Product Description: Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy[1][2].
Applications: COVID-19-anti-virus
Formula: C20H19NO4
References: [1]Yu D, et al. Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells. PLoS One. 2017 Aug 1;12(8):e0181823./[2]Li C, et al. Dihydroberberine, an isoquinoline alkaloid, exhibits protective effect against dextran sulfate sodium-induced ulcerative colitis in mice. Phytomedicine. 2021 Sep;90:153631.
CAS Number: 483-15-8
Molecular Weight: 337.37
Compound Purity: 98.44
Research Area: Cancer; Inflammation/Immunology; Cardiovascular Disease
Solubility: DMSO : 20 mg/mL (ultrasonic;warming;heat to 70°C)
Target: HSP;Potassium Channel